Dr. Andrea Sautter

Andrea is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group.

Her practice includes advising national and international pharmaceutical and biotech companies, medical product manufacturers and food product producers on intellectual property law and regulatory issues. A focus of her practice is advising on complex, often cross-border, projects, in particular research and development cooperations, manufacturing and distribution agreements and licences, as well as advice on transactions.

Afficher le CV complet Masquer le CV complet

Carrière

Since 2020	Salary Partner, Taylor Wessing
2015 – 2019	Senior Associate, Taylor Wessing
Since 2012	Lecturer for presentation methods, University of Mannheim

2010 – 2012

Research and teaching Assistant, Institute for Medical Law of the Universities of Heidelberg and Mannheim (IMGB)

Voir plus Moins

Formation

2018	Ph.D. in law, University of Mannheim
2015	Admitted as a lawyer, Munich
2015	Second state examination, Wiesbaden

2013 – 2015	Legal clerkship including stages at an international law firm in Frankfurt; the legal department of a healthcare corporation in Bad Homburg v.d.H and the German Desk of a Korean law firm in Seoul
2012	Additional qualification in pharmaceutical law, University in Marburg
2010	First state examination
2005 – 2010	Legal studies, University of Mannheim

Voir plus Moins

Langues étrangères

English

Expertise

Services et Groupes Brevets et innovation

Secteurs Sciences de la vie et Santé Biotech Cosmétiques, alimentation et compléments alimentaires Dispositifs médicaux Produits pharmaceutiques

Experience

Formycon	Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.
Hauck & Aufhäuser	A Taylor Wessing team led by Frankfurt-based partners Lars-Gerrit Lüßmann and Ulrich Reers advised Hauck & Aufhäuser Investment Banking and Polish universal bank mBank in their role as exchange trustee and settlement agent on the voluntary public takeover/exchange offer by Frankfurt-listed Vita 34 AG, Leipzig, to the shareholders of Warsaw-listed stem cell bank Polski Bank Komórek Macierzystych S.A, Warsaw (PBKM). The transaction is the first cross-border exchange offer for a Polish listed company to date.
Steadfast Capital Fund IV on the acquisition of a majority stake in Söhngen Group	Steadfast Capital Fund IV on the acquisition of a majority stake in Söhngen Group. The transaction included both W. Söhngen GmbH based in Taunusstein (Hesse) and Silva GmbH based in Mainhausen (Hesse). The parties have agreed not to disclose the purchase price. The majority acquisition aims to support further growth of the Söhngen Group with its internationally recognised brands and premium products in the market for first aid and emergency medical products both organically and through acquisitions. We also advised on the financing of the acquisition.

Prix et distinctions

JUVE Awards 2023	Law firm of the year for IP Law
Legal 500 Germany 2023	Key lawyer for Healthcare

Actualités et publications récentes

Contrats commerciaux et Consommation

Medical devices & the EU draft regulation on AI – new challenges for my business?

27 novembre 2023

In-depth analysis

par plusieurs auteurs

Cliquer ici pour en savoir plus

Brevets et innovation

JUVE Awards 2023: Taylor Wessing named "Law Firm of the Year for IP”

27 octobre 2023

par plusieurs auteurs

Cliquer ici pour en savoir plus

Produits pharmaceutiques

Current developments in the field of clinical drug trials in Germany - adjusting parameters to shorten procedures before the start of a clinical trial

13 octobre 2023

Briefing

par Dr. Andrea Sautter et Sarah Aschenbrenner

Cliquer ici pour en savoir plus